Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio. Sanifit, based in Palma (Spain) has had the backing of international and Spanish funds, among which are the CataloniaBio  & HealthTech members Alta Life Sciences, Ysios Capital and Healthequity, as well as Caixa Capital Risc, Columbus Venture Partners, and Innvierte from CDTI.

Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company’s portfolio of innovative assets. Shareholders of Sanifit will receive an upfront payment of EUR 205 million, clinical, regulatory and market access milestones for up to EUR 170 million and tiered sales-based milestones that could reach mid to high triple digit EUR millions at peak sales.

Joël  Jean-Mairet, Managing Partner of Ysios Capital comments: “We are very proud to have supported Sanifit in its evolution and to see that it has become a success story that will undoubtedly serve as inspiration for other Spanish companies in the early stages”. Jose Antonio Mesa, Alta Life Sciences partner, also highlights "This transaction is a clear demonstration of the level of maturity that companies, entrepreneurs and investors are reaching in the biotechnology sector in Spain".